Drug intelligence / Profile preview

China Pharma Univ. SHP2 compound A8

Development stage: Preclinical
Lead developer: China Pharmaceutical University

Overview

China Pharma Univ. SHP2 compound A8: sourced facts only. name: "A8, the most potential SHP2 inhibitor, exhibited great antiproliferative activities against SHP099/TNO155-insensitive tumor cell lines, and rescued PD-L1-mediated immunosuppression." [PMID:39541871]; target: "A8, the most potential SHP2 inhibitor, exhibited great antiproliferative activities against SHP099/TNO155-insensitive tumor cell lines, and rescued PD-L1-mediated immunosuppression." [PMID:39541871]; developer: "School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China." [PMID:39541871]; stage: "A8 significantly suppressed in vivo tumor growth in a CT26 mouse model and activated immunomodulatory effects in tumor microenvironment." [PMID:39541871]

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on China Pharma Univ. SHP2 compound A8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Pharma Univ. SHP2 compound A8.